Background
Methods
JBCRG22 study
Pathological assessment of treatment response
Multiplex fluorescent immunohistochemistry
Statistical analysis
Results
Background characteristics of patients
Treatment group | Total | A1 | A2 | B1 | B2 | |
---|---|---|---|---|---|---|
Patient number | 66 | 15 | 18 | 17 | 16 | |
Age, years | Median | 54 | 44 | 47 | 58 | 56 |
min.–max. | 26–70 | 31–64 | 26–63 | 35–70 | 41–70 | |
T | T1c | 13 | 5 | 3 | 2 | 3 |
T2 | 48 | 9 | 13 | 14 | 12 | |
T3 | 5 | 1 | 2 | 1 | 1 | |
N | N0 | 39 | 7 | 11 | 11 | 10 |
N1 | 27 | 8 | 7 | 6 | 6 | |
Histological grade (B and R) | 1 | 2 | 1 | 0 | 0 | 1 |
2 | 17 | 2 | 4 | 5 | 6 | |
3 | 44 | 11 | 14 | 11 | 8 | |
Unknown | 3 | 1 | 0 | 1 | 1 | |
Ki67 labeling index, % | Median | 57.7 | 55 | 64.2 | 51.6 | 50.4 |
min.–max. | 16.2–90 | 20.2–90 | 36.4–89.6 | 20–89 | 16.2–82 | |
HRD | Low | 18 | 0 | 0 | 9 | 9 |
High | 33 | 15 | 18 | 0 | 0 | |
Unknown | 15 | 0 | 0 | 8 | 7 | |
tBRCA1/2 mutation | BRCA1 mutation | 6 | 3 | 3 | 0 | 0 |
BRCA2 mutation | 6 | 3 | 3 | 0 | 0 | |
No mutation | 43 | 9 | 12 | 12 | 10 | |
Unknown | 11 | 0 | 0 | 5 | 6 | |
pCR | Yes | 23 | 10 | 8 | 2 | 3 |
No | 43 | 5 | 10 | 15 | 13 | |
% | 34.8 | 66.7 | 44.4 | 11.8 | 18.8 |
Immune cells in cancer tissues in association with background characteristics
Tumor BRCA1/2 mutation and HRD status and immune cells
Treatment response and immune cells
Intratumoral CD4 | Stromal CD4 | |||||
---|---|---|---|---|---|---|
HR | 95% CI | P value | HR | 95% CI | P value | |
Age | 0.93 | 0.853–1.011 | 0.072 | 0.9 | 0.821–0.996 | 0.024 |
Dose | 1.073 | 1.005–1.147 | 0.0073 | 1.059 | 0.994–1.13 | 0.032 |
HRD | 0.92 | 0.848–1.005 | 0.053 | 0.92 | 0.841–1.007 | 0.058 |
Treatment | 0.035 | 0.026 | ||||
A1 | Reference | Reference | ||||
A2 | 0.48 | 0.35 | ||||
B1 | 2.61×10−11 | 1.92×10−11 | ||||
B2 | 0.016 | 0.013 | ||||
Intratumoral CD4 | 1.008 | 0.997–1.019 | 0.009 | |||
Stromal CD4 | 1.0023 | 1.0002–1.0044 | 0.0057 |
Platinum-containing chemotherapy (groups A1 + A2) | ||||||
HR | 95% CI | P value | HR | 95% CI | P value | |
Age | 0.89 | 0.809–0.980 | 0.0066 | 0.88 | 0.797–0.973 | 0.0038 |
Dose | 1.041 | 0.970–1.117 | 0.25 | 1.029 | 0.963–1.099 | 0.38 |
Treatment | 0.32 | 0.19 | ||||
A1 | Reference | Reference | ||||
A2 | 0.39 | 0.29 | ||||
Intratumoral CD4 | 1.009 | 0.996–1.022 | 0.018 | |||
Stromal CD4 | 1.002 | 1.000–1.004 | 0.022 | |||
Non-platinum-containing chemotherapy (groups B1 + B2) | ||||||
HR | 95% CI | P value | HR | 95% CI | P value | |
Age | 1.02 | 0.893–1.169 | 0.75 | 1.009 | 0.883–1.153 | 0.89 |
Dose | 1.091 | 0.975–1.222 | 0.022 | 1.096 | 0.968–1.241 | 0.029 |
Treatment | 0.42 | 0.70 | ||||
B1 | Reference | Reference | ||||
B2 | 2.47 | 1.573 | ||||
Intratumoral CD4 | 0.998 | 0.994–1.003 | 0.38 | |||
Stromal CD4 | 1.0003 | 0.998–1.002 | 0.73 |